BIBF 1120 in Recurrent Glioblastoma Multiforme
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01251484|
Recruitment Status : Completed
First Posted : December 2, 2010
Last Update Posted : October 4, 2012
VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.
VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional, recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Glioblastoma||Drug: BIBF1120||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||August 2012|
- Response rate [ Time Frame: Response evaluation every 8 weeks ]MacDonald criteria
- Adverse events [ Time Frame: Assessed every 2 weeks ]CTCAE version 4.0
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01251484
|Copenhagen, Denmark, 2100|